Management at Varian Medical Systems Oncology Systems business unit has been restructured to consolidate global operations and provide additional management resources for developing early-stage emerging businesses, according to company CEO and president
Management at Varian Medical Systems Oncology Systems business unit has been restructured to consolidate global operations and provide additional management resources for developing early-stage emerging businesses, according to company CEO and president Richard M. Levy. Tim Guertin is the company's new executive vice president. Guertin will continue as president of Varian's Oncology Systems business in addition to assisting Levy with corporate issues. Several other new appointments were made within Oncology Systems.
John Ford, corporate vice president, has been named senior vice president for Oncology Systems, responsible for facilitating major customer, government, and partnering initiatives. Jeff Marcus, vice president of Oncology Systems, will assume responsibility for the worldwide sales organization. Paul Rowland, vice president of North American sales, Oncology Systems, will head the sales organization in the U.S. and Canada. He will report to Marcus. The medical manufacturing operations for Oncology Systems will be combined under Keith Krugman, corporate vice president and vice president, Oncology Systems, who will have continuing responsibility for worldwide customer support functions. Elaine McKinley has been appointed vice president, Oncology Systems customer support, reporting to Krugman. Product engineering and marketing have been combined under the direction of Kolleen Kennedy, vice president, Oncology Systems. Ueli Graf, vice president, worldwide engineering, Oncology Systems, will report to Kennedy.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.